Press Releases

All Releases
View Summary Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
May 14, 2015
PDF 13.2 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results
May 7, 2015
PDF 20.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer
May 5, 2015
PDF 15.7 KB Add to Briefcase
View Summary Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
May 4, 2015
PDF 14.9 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of First Quarter 2015 Investor Conference Call and Presentation at Credit Suisse 2015 Antibody Conference
Apr 28, 2015
PDF 13.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Apr 27, 2015
PDF 16.9 KB Add to Briefcase
View Summary First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients
Apr 21, 2015
PDF 63.6 KB Add to Briefcase
View Summary Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer
Apr 20, 2015
PDF 18.2 KB Add to Briefcase
View Summary Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting
Mar 26, 2015
PDF 14.5 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results
Feb 26, 2015
PDF 26.6 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer
Feb 19, 2015
PDF 20.0 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call
Feb 12, 2015
PDF 15.1 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors
Jan 22, 2015
PDF 17.7 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
Jan 20, 2015
PDF 26.8 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
Jan 8, 2015
PDF 17.0 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Jan 7, 2015
PDF 15.2 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors
Dec 17, 2014
PDF 17.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
Dec 12, 2014
PDF 22.9 KB Add to Briefcase
View Summary Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research
Dec 4, 2014
PDF 18.3 KB Add to Briefcase
View Summary Merrimack Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference, Hold Analyst Day and Present Research on Multiple Molecules in December 2014
Dec 1, 2014
PDF 19.1 KB Add to Briefcase
Showing 1-20 of 161 Page: 1 2 3 4 5 ... 9  Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ: MACK)

Price:
12.56

Change:
+ 0.10

Day High:
12.69

Day Low:
12.38

Volume:
584,400

4:00 PM ET on May 22, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools